| Biomanufacturing (22) |  |
| Bioscience (62) | |
| Biotechnology (220) | |
| Biotechnology companies (70) | |
| Biotechnology industry (7) | |
| Biotechnology product (5) | |
| Red biotechnology (40) | |
| White biotechnology (6) | |
| Biomanufacturing (22) | |
| Bioscience (62) | |
| Biotechnology (220) | |
| Biotechnology companies (70) | |
| Biotechnology industry (7) | |
| Biotechnology product (5) | |
| Red biotechnology (40) | |
| White biotechnology (6) | |
The group includes researchers at the Icahn School of medicine at Mount sinai Washington University the University of Texas Southwestern Medical center Howard University and Microbiotix Inc. a Massachussetts biopharmaceutical company Source:
They will be awarded every two years starting in 2014, to global leaders in the fields of sustainable development, biopharmaceutical science, Chinese studies and the rule of law.
and the biopharmaceutical company Metabolic Solutions Development Co. The company is involved in clinical trials that are evaluating the drug compound MSDC-0602 as a treatment for diabetes.
"said Ghodbane, who now works in biopharmaceutical research and development at Glaxosmithkline. The breakthrough also requires one-tenth of the chemicals used in a conventional multiplex immunoassay,
who earned his doctorate in biomedical engineering at Rutgers and now works in biopharmaceutical research and development at Glaxosmithkline.
who now works in biopharmaceutical research and development at Glaxosmithkline, published their results in the journal Lab on a Chip in addition to being able to use less fluid,
as a biopharmaceutical component or as a natural insect repellent.""We have installed new genetic information in the yeast Pichia pastoris,
Biopharmaceuticals, or biologics, are produced proteins by living cells. Proteins such as catalase are tens of thousands of times larger than the small molecules that make up traditional drugs.
who earned his doctorate in biomedical engineering at Rutgers and now works in biopharmaceutical research and development at Glaxosmithkline.
#New Single-use Harvesting Technology for High Cell Density Cultures Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, has introduced Sartoclear Dynamics,
a clinical stage biopharmaceutical company which owns the core T-cell receptor technology and funded the study.
The biopharmaceutical industry is an important contributor to U s. economic growth and sustainability, with more than 650,000 direct jobs (supporting a total of nearly 4 million jobs) and an economic output that totals more than $900 billion
As a result, gains and losses in the biopharmaceutical sector cascade across many important economic sectors in the U s. It is becoming clear,
however, that the U s. can no longer take its leadership in biopharmaceuticals or other knowledge-based industries for granted.
many of which are targeted to the biopharmaceutical industry and related sectors. Despite the short-term costs associated with these investments,
As a result, more and more, the U s. is competing globally to maintain its leadership position in biopharmaceuticals.
For purposes of this study, entitled The Biopharmaceutical Research and development Enterprise: Growth Platform for Economies Around the World, Battelle examined policies
In addition, countries selected include a mix of developed countries with an existing biopharmaceutical presence (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, Sweden, the United kingdom UK,
and the E u. as a whole) and emerging countries that are targeting the biopharmaceutical sector (Brazil, Chile, China, Russia, Saudi arabia, Singapore, South africa, and South korea).
and capital, all of the countries examined are focusing on strategic components to grow their biopharmaceutical economy.
and programs to increase the economic footprint of the biopharmaceutical and related sectors in their own countries.
America innovative biopharmaceutical companies face increasing challenges, ranging from the cost and increased complexity of bringing new medicines to patients, the prospect of attracting
Just as other countries have drawn lessons from the growth of the U s. biopharmaceutical sector so too can the U s. learn from other countries that are strategically
according to Michael Egholm, president of Pall Biopharmaceuticals. The AWS technology works by applying acoustic forces across a flow channel to generate a three-dimensional standing wave.
but accelerating, a phenomenon that is reflected in the timing of biopharmaceutical product launches: Since the first biopharmaceutical drug Humulin was launched in 1982 to the beginning of this decade (between 1982 and 2009 27 year period),
there were 117 biopharmaceutical approvals. That an impressive number, but there have been 67 approvals between 2010 and 2014 four year period.
Roughly speaking, biopharmaceutical product launches increased from around 4 to nearly 17 approvals per year. Biopharmaceutical production is increasing not only through the introduction of novel therapeutics,
but also through the introduction of biosimilars or generic biopharmaceuticals, which can be manufactured by several companies.
The market for cell cultures is expected to grow rapidly alongside biopharmaceuticals and with significant evolution in culture technology.
Cell Line Trends Many biopharmaceuticals are produced by bacteria especially the species Escherichia coli and Bacillus subtilis. E coli has been studied in microbiology laboratories for many years
and was the first organism to have its entire genome mapped. It is inexpensive to cultivate,
it replicates quickly, and it serves as a good model organismhat is, it provides an example of how other similar life forms will behaveuch as how they grow
The rising stakes and production levels of companies active in biopharmaceuticals have dictated improved reproducibility or consistency in product;
The biopharmaceutical industry shift away from animal-derived culture products is expected to continue, particularly given the ascension of mammalian cell lines in biopharmaceutical production.
Serum-free media is the more complex composition designed for universal use in culturing mammalian cell lines.
Working and Master Cell Banks Once a biopharmaceutical company obtains a beginning cell bank from a cell culture collection,
This technology was licensed by the Biopancreate a wholly-owned subsidiary of Cortendo AB a biopharmaceutical company incorporated in Sweden
a private British biopharmaceutical company focused on the development of therapies for retinal dystrophies. e are leading the way in the development of an effective gene therapy treatment for choroideremia,
and neutralize Marburg virushich has a mortality rate of up to 90%ere developed through an academic-industrial partnership including TSRI, Integrated Biotherapeutics, Mapp Biopharmaceutical and Emergent biosolutions.
Other antibodies in the study were identified independently at Mapp Biopharmaceutical and Integrated Biotherapeutics which collaborated with TSRI for molecular analysis. Some of the new antibodies target a new site on Marburg virus not seen before winglike feature attached to the base of the virus. Antibodies against this newly discovered site protected 90 to 100%of infected animal models from lethal infection.
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011